Two is Better Than One: A Novel Venous Access System for Intermittent Apheresis
- Conditions
- Apheresis
- Interventions
- Device: PowerPort
- Registration Number
- NCT04846374
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Brief Summary
Purpose: To describe a novel configuration of venous access for the performance of intermittent apheresis.
Participants: 20 participants at UNC who were referred for change from a vortex port to a powerflow port.
Procedures (methods): Placement of one of two configurations of the powerflow port and follow up visits between January 1, 2019 and December 31, 2023.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
- Over the age of 18 years of age.
- Referred for change from a vortex port to a powerflow port.
- Previously placed or scheduled placement of one of two configurations of the PowerFlow port
- Unable to read and understand English.
- Unable to provide informed consent.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description PowerPort Subjects PowerPort This study will involve a chart review of patients at UNC who were referred for change from a vortex port to a powerflow port.
- Primary Outcome Measures
Name Time Method Change in Flow Rate 1 year following new port configuration placement The study will compare mean change flow rate for pheresis sessions with the old system versus pheresis sessions with one of two new configurations by averaging the flow rate for up to 5 sessions using the new port configuration.
Change in Procedure Time 1 year following new port configuration placement The study will compare mean change in procedure time for pheresis sessions with the old system versus pheresis sessions with one of two new configurations.
- Secondary Outcome Measures
Name Time Method Change in Use of Tissue Plasminogen Activator 1 year following new port configuration placement The study will compare mean change in use of tissue plasminogen activator for pheresis sessions with the old system versus pheresis sessions with one of two new configurations.
Trial Locations
- Locations (1)
University of North Carolina at Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States